SciSparc Ltd. Overview
Pro stress-test →SciSparc is a specialty clinical-stage pharmaceutical company focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company conducts its core pharmaceutical activities through its majority-owned subsidiary NeuroThera Labs Inc., a publicly traded company on the TSX Venture Exchange in Canada.
Strategic Profile
Pro stress-test →Through NeuroThera Labs, the company reports progress on cannabinoid-based drug candidates, patent grants, and collaborations targeting central nervous system and neuropsychiatric disorders. Recent corporate transactions include the transfer of its advanced clinical-stage pharmaceutical portfolio to NeuroThera Labs and the sale of its oncology-focused subsidiary MitoCareX Bio Ltd.
Competitive Landscape
Pro stress-test →Comparable companies in the biotech/pharma sector include Unity Btech, Revelation Biosciences, Indaptus Therapeutics, Protagenic Therapeutics, and Lipella Pharmaceuticals. SciSparc competes in the cannabinoid and psychedelic-based therapeutics space with emerging companies like Clearmind Medicine and established cannabis-focused biotech firms.
Industry Context
SciSparc Ltd. operates in Pharmaceutical/Biotechnology - Clinical-Stage Cannabinoid and Psychedelic Therapeutics.
Key facts
Founded: 2004 · Headquarters: Tel Aviv-Yafo, IL · Employees: 2 · Revenue: Not disclosed · Market cap: $2.84M